Clinical Trials Browser

Phase 3 × Squamous Cell Carcinoma of Head and Neck × 30 days × Clear all

NCT00588770 2026-05-26

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 3 Active not recruiting

403 enrolled 10 charts

Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT06256588 2026-05-26

JADE

Phase 3 Recruiting

864 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06589804 2026-05-22

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

Phase 3 Recruiting

158 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT07264075 2026-05-20

ILLUMINE

Phase 3 Recruiting

780 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06496178 2026-05-18

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

Phase 3 Recruiting

600 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT07580300 2026-05-15

PRORADNOR-RCT

Phase 3 Recruiting

400 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04892173 2026-05-11

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Phase 3 Recruiting

500 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT06992427 2026-05-11

HOPE

Phase 3 Recruiting

228 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06525220 2026-05-08

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Phase 3 Recruiting

700 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT07276399 2026-05-08

OrigAMI-5

Phase 3 Recruiting

500 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04199104 2026-05-05

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

Phase 3 Completed

511 enrolled 20 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05721755 2026-05-05

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 3 Active not recruiting

290 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07441681 2026-05-04

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

Phase 3 Not yet recruiting

454 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms